Immune Checkpoint Therapy in Melanoma

Margaret K Callahan

doi:10.1097/PPO.0000000000000183

Immune Checkpoint Therapy in Melanoma

Cancer J. 2016 Mar-Apr;22(2):73-80. doi: 10.1097/PPO.0000000000000183.

Author

Margaret K Callahan¹

Affiliation

¹ From the Melanoma and Immunotherapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center; and Weill Medical College, Cornell University, New York, NY.

PMID: 27111901
DOI: 10.1097/PPO.0000000000000183

Abstract

Checkpoint-blocking antibodies have transformed cancer therapy, and the treatment of patients with metastatic melanoma has led the revolution. Herein, we review the current clinical data supporting the use of checkpoint-blocking antibodies in the treatment of melanoma and highlight outstanding clinical questions and unmet clinical needs.

Publication types

Review

MeSH terms

Animals
Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors
B7-H1 Antigen / metabolism
CTLA-4 Antigen / antagonists & inhibitors
CTLA-4 Antigen / metabolism
Clinical Trials as Topic
Combined Modality Therapy
Humans
Immunomodulation / drug effects*
Melanoma / immunology*
Melanoma / metabolism
Melanoma / pathology
Melanoma / therapy*
Molecular Targeted Therapy*
Neoplasm Staging
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / metabolism
T-Lymphocyte Subsets / drug effects
T-Lymphocyte Subsets / immunology
T-Lymphocyte Subsets / metabolism
Treatment Outcome

Substances

Antibodies, Monoclonal
Antineoplastic Agents
B7-H1 Antigen
CTLA-4 Antigen
Programmed Cell Death 1 Receptor